James Daly Sells 30,000 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Director James Daly sold 30,000 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $22.37, for a total transaction of $671,100.00. Following the completion of the transaction, the director directly owned 4,041 shares of the company’s stock, valued at approximately $90,397.17. The trade was a 88.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

ACADIA Pharmaceuticals Price Performance

ACAD opened at $23.64 on Friday. The company has a market capitalization of $4.00 billion, a price-to-earnings ratio of 17.77, a P/E/G ratio of 7.90 and a beta of 0.80. The business’s 50-day moving average price is $22.44 and its two-hundred day moving average price is $22.14. ACADIA Pharmaceuticals Inc. has a 1 year low of $13.40 and a 1 year high of $26.65.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.28. ACADIA Pharmaceuticals had a return on equity of 14.69% and a net margin of 21.80%.The business had revenue of $278.63 million during the quarter, compared to the consensus estimate of $276.52 million. During the same period last year, the company earned $0.20 earnings per share. ACADIA Pharmaceuticals’s quarterly revenue was up 11.3% on a year-over-year basis. ACADIA Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Geneos Wealth Management Inc. raised its holdings in shares of ACADIA Pharmaceuticals by 113.0% in the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 756 shares during the period. Banque Transatlantique SA bought a new position in ACADIA Pharmaceuticals during the first quarter worth about $31,000. Picton Mahoney Asset Management acquired a new position in ACADIA Pharmaceuticals during the first quarter worth approximately $32,000. Smartleaf Asset Management LLC raised its stake in ACADIA Pharmaceuticals by 107.0% in the third quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 885 shares during the period. Finally, Federated Hermes Inc. lifted its position in shares of ACADIA Pharmaceuticals by 231.5% in the first quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 1,618 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ACAD shares. JPMorgan Chase & Co. lowered their price objective on shares of ACADIA Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a report on Monday, September 29th. Cowen reiterated a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, September 11th. Citigroup initiated coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, October 21st. They set a “buy” rating and a $33.00 price target on the stock. UBS Group raised their price objective on ACADIA Pharmaceuticals from $36.00 to $39.00 and gave the company a “buy” rating in a report on Tuesday, September 9th. Finally, Royal Bank Of Canada lowered their target price on ACADIA Pharmaceuticals from $34.00 to $32.00 and set an “outperform” rating on the stock in a research report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.94.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.